ATE59409T1 - Herstellung von oberflaechen-hepatitis-b-antigen in hefe. - Google Patents

Herstellung von oberflaechen-hepatitis-b-antigen in hefe.

Info

Publication number
ATE59409T1
ATE59409T1 AT82304513T AT82304513T ATE59409T1 AT E59409 T1 ATE59409 T1 AT E59409T1 AT 82304513 T AT82304513 T AT 82304513T AT 82304513 T AT82304513 T AT 82304513T AT E59409 T1 ATE59409 T1 AT E59409T1
Authority
AT
Austria
Prior art keywords
yeast
hepatitis
hbsag
antigens
gene
Prior art date
Application number
AT82304513T
Other languages
English (en)
Inventor
Ronald A Hitzeman
Arthur D Levinson
Daniel G Yansura
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23149637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE59409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE59409T1 publication Critical patent/ATE59409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT82304513T 1981-08-31 1982-08-26 Herstellung von oberflaechen-hepatitis-b-antigen in hefe. ATE59409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29823681A 1981-08-31 1981-08-31
EP82304513A EP0073657B1 (de) 1981-08-31 1982-08-26 Herstellung von Oberflächen-Hepatitis-B-Antigen in Hefe

Publications (1)

Publication Number Publication Date
ATE59409T1 true ATE59409T1 (de) 1991-01-15

Family

ID=23149637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82304513T ATE59409T1 (de) 1981-08-31 1982-08-26 Herstellung von oberflaechen-hepatitis-b-antigen in hefe.

Country Status (10)

Country Link
EP (1) EP0073657B1 (de)
JP (1) JP2511394B2 (de)
AT (1) ATE59409T1 (de)
AU (1) AU560122B2 (de)
DE (1) DE3280284D1 (de)
GB (1) GB2104902B (de)
HK (1) HK37494A (de)
IE (1) IE56711B1 (de)
NZ (1) NZ201705A (de)
ZA (1) ZA826251B (de)

Families Citing this family (339)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE53235T1 (de) * 1981-08-04 1990-06-15 Univ California Synthese von menschlichen viralen antigenen mit hilfe von hefe.
DK368882A (da) * 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
EP0105149B1 (de) * 1982-08-16 1990-05-16 Science and Technology Agency, Minister's Secretariat, Director of Finance Division Hepatitis-B-Virus-Gen enthaltendes rekombinantes Plasmid, mit diesem rekombinanten Plasmid transformierte Hefe und Herstellung von Hepatitis-B-Virus-Oberflächenantigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
EP0116201B1 (de) * 1983-01-12 1992-04-22 Chiron Corporation Sekretorische Expression in Eukaryoten
CA1341302C (en) * 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US5089398A (en) * 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
GB8314961D0 (en) * 1983-05-31 1983-07-06 Kingsman A J Dna sequence
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
JPS60192591A (ja) * 1984-03-12 1985-10-01 Japan Found Cancer 成人ｔ細胞白血病ウイルス抗原ポリペプチド
JPS60196185A (ja) * 1984-03-19 1985-10-04 Chemo Sero Therapeut Res Inst 形質転換酵母の培養方法
DE3587759T2 (de) * 1984-05-11 1994-07-07 Chiron Corp Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4880734A (en) * 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
EP0401941A3 (de) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung
JPS6170989A (ja) * 1984-09-13 1986-04-11 Takeda Chem Ind Ltd 組み換えｄｎａおよびその用途
US7393949B1 (en) 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US7273695B1 (en) * 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
JP2594535B2 (ja) * 1984-11-30 1997-03-26 サントリー株式会社 高発現ベクターおよびその利用
DE3689899T2 (de) * 1985-04-08 1994-09-15 Amgen Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1993012815A1 (en) * 1991-12-27 1993-07-08 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis b, antigen and vaccine based on it
LT3988B (en) 1992-02-17 1996-06-25 Fermentas Biotech Inst Recombinant plasmides pfs19, pfps2-48 and pjlfds1 codingsynthesis of human hepatite b of surfice virus antigenes, methods fof producing thereof
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US6077510A (en) * 1995-01-06 2000-06-20 Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6113905A (en) * 1995-01-06 2000-09-05 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US6015660A (en) * 1995-01-06 2000-01-18 The Regents Of The University Of California Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
EP1500702A1 (de) 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 Apoptosis Polypeptides aus der TNFR1 Familie
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
EP2371962A3 (de) 1996-12-23 2011-12-21 Immunex Corporation Ligand für Rezeptor Aktivator von NF-KAPPA B, Ligand ist Mitglied der TNF Superfamilie
CA2277266A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
WO2000039297A2 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU739350B2 (en) 1997-06-05 2001-10-11 University Of Texas System, The APAF-1, the CED-4 human homolog, an activator of caspase-3
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
WO1999002721A1 (en) 1997-07-11 1999-01-21 University Of North Texas THE ESCHERICHIA COLI csrB GENE, RNA ENCODED THEREBY, AND METHODS OF USE THEREOF
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
ES2313756T3 (es) 1997-10-29 2009-03-01 Genentech, Inc. Usos de polipeptido secretado wisp-1 inducido por wnt-1.
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2288649T3 (es) 1997-11-21 2008-01-16 Genentech, Inc. Antigenos tipo a-33 y sus utilizaciones farmacologicas.
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
DK2016951T3 (da) 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
NZ510497A (en) 1998-08-21 2003-09-26 Immunex Corp Human IL-1 epsilon DNA and polypeptides
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
EP1661996A1 (de) 1999-12-01 2006-05-31 Genentech, Inc. Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
NZ520171A (en) 1999-12-20 2005-07-29 Immunex Corp Tweak receptor
EP2163625B1 (de) 1999-12-23 2014-05-21 Genentech, Inc. IL-17 und IL-17R-homologe Polypeptide und ihre therapeutische Verwendung
US6555335B1 (en) 1999-12-30 2003-04-29 Genencor International, Inc. Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme
DE60137829D1 (de) 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
EP1265849B1 (de) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP2077276A1 (de) 2000-06-23 2009-07-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
JP2004502664A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
EP1303293B1 (de) 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
EP2014298A3 (de) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100628425B1 (ko) 2001-06-20 2006-09-28 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP1427830B1 (de) 2001-08-29 2012-05-09 Genentech, Inc. Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
NZ573742A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT212
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2067472A1 (de) 2002-01-02 2009-06-10 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
EP1575480A4 (de) 2002-02-22 2008-08-06 Genentech Inc Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method
JP2006517384A (ja) 2002-07-08 2006-07-27 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
ATE493433T1 (de) 2002-09-11 2011-01-15 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
ATE492631T1 (de) 2002-09-13 2011-01-15 Cornell Res Foundation Inc Verwendung von mutationen zur verbesserung von aspergillus-phytasen
CA2498274A1 (en) 2002-09-16 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
WO2004031376A2 (en) 2002-10-04 2004-04-15 Firmenich Sa Sesquiterpene synthases and methods of use
EP2322203A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2311868A1 (de) 2002-11-26 2011-04-20 Genentech, Inc. Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
JP2006516408A (ja) 2003-02-01 2006-07-06 タノックス インコーポレーテッド 高親和性抗体の生成方法
MXPA05009743A (es) 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
KR20160114727A (ko) 2003-05-30 2016-10-05 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
PT2784084T (pt) 2003-07-08 2019-10-01 Genentech Inc Anticorpos antagonistas contra polipéptidos heterólogos il-17a/f
US7442785B2 (en) 2003-07-24 2008-10-28 The University Of Kentucky Research Foundation Sesquiterpene synthase gene and protein
ATE554108T1 (de) 2003-07-25 2012-05-15 Amgen Inc Verfahren bezüglich ldcam und crtam
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
PL2295073T3 (pl) 2003-11-17 2014-09-30 Genentech Inc Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
MXPA06007856A (es) 2004-01-07 2007-03-23 Chiron Corp Anticuerpo monoclonal especifico de factor de estimulacion de colonias de macrofagos (m-csf) y usos del mismo.
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
JP2008503217A (ja) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド 新規抗原結合ポリペプチド及びそれらの使用
BRPI0513534A (pt) 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
BRPI0519568C8 (pt) 2004-12-22 2022-06-14 Ambrx Inc Aminoacil-trna sintetase (rs), composições que compreendem a dita aminoacil-trna sintetase, célula de levedura, célula fúngica, célula não eucariótica, vetor que codifica uma rs, polinucleotídeo e ainda método para produzir um polipeptídeo em uma célula com um aminoácido selecionado em uma posição especificada
DK2399893T3 (en) 2004-12-22 2018-10-08 Ambrx Inc COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
EP1841793B1 (de) 2005-01-07 2010-03-31 Diadexus, Inc. Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
NZ565294A (en) 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20090018029A1 (en) 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
EA016245B9 (ru) 2005-11-18 2013-04-30 Гленмарк Фармасеутикалс С.А. Антитела против альфа2-интегрина и их применение
JP2009516514A (ja) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド 新規遺伝子破壊、それらに関する組成物および方法
CN101448512B (zh) 2005-12-14 2015-11-25 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
EP2385125A3 (de) 2005-12-21 2012-04-11 Inspiration Biopharmaceuticals, Inc. Verfahren zur Herstellung von Biologisch aktiven Vitamin K-abhängigen Proteinen aus rekombinanten Verfahren
JP2009527227A (ja) 2006-02-17 2009-07-30 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
AU2007227224A1 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP2027291A2 (de) 2006-04-27 2009-02-25 Pikamab, Inc. Verfahren und zusammensetzungen für antikörpertherapie
AU2007247969A1 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to ZPA polypeptides
AU2007276294B2 (en) 2006-06-30 2012-11-29 Novo Nordisk A/S Anti-NKG2A antibodies and uses thereof
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
EP2420252A1 (de) 2006-08-04 2012-02-22 Novartis AG EPHB3-spezifischer Antikörper und Verwendungen davon
TWI454480B (zh) 2006-08-18 2014-10-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
BRPI0716680A2 (pt) 2006-11-02 2013-09-24 Daniel J Capon "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo"
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
EP2962697A1 (de) 2006-11-27 2016-01-06 diaDexus, Inc. Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
EP2101816B1 (de) 2006-12-07 2013-08-14 Novartis AG Antagonistische antikörper gegen ephb3
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
WO2008103962A2 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
DK2068909T3 (da) 2007-03-30 2012-08-06 Ambrx Inc Modificerede FGF-21-polypeptider og anvendelse heraf
CA3090908A1 (en) 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
BRPI0810622A2 (pt) 2007-05-02 2020-10-13 Ambrx, Inc. polipeptídeos de interferon beta modificados e seus usos
JP2010533495A (ja) 2007-07-16 2010-10-28 ジェネンテック， インコーポレイテッド ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
CA2704973A1 (en) 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
CN104059143A (zh) 2007-11-12 2014-09-24 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
CN101918026B (zh) 2007-11-20 2016-03-02 Ambrx公司 经修饰胰岛素多肽和其用途
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2009114560A2 (en) 2008-03-10 2009-09-17 Spaltudaq Corporation Compositions and methods for the therapy and diagnosis of cytomegalovirus
EP3208612B1 (de) 2008-04-09 2019-09-18 Genentech, Inc. Zusammensetzungen und verfahren zur behandlung von immunbedingten erkrankungen
EP2291399B1 (de) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Polyvalente proteine mit fibronectin-gerüstdomänen
BRPI0916515B8 (pt) 2008-07-23 2021-07-27 Ambrx Inc polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
US8815794B2 (en) 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
UA106731C2 (uk) 2008-09-26 2014-10-10 Амбркс, Інк. Модифіковані поліпептиди еритропоетину тварин та їх застосування
PT2337846T (pt) 2008-09-26 2018-04-05 Ambrx Inc Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
NZ592436A (en) 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
KR20110104052A (ko) 2008-12-16 2011-09-21 노파르티스 아게 효모 디스플레이 시스템
MX2011006516A (es) 2008-12-17 2011-08-04 Genentech Inc Terapia de combinacion de virus de hepatitis c.
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
KR20170124619A (ko) 2009-03-27 2017-11-10 아카데미아 시니카 바이러스에 대한 면역을 위한 방법 및 조성물
NZ595574A (en) 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
CA2762302A1 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US8765431B2 (en) 2009-07-23 2014-07-01 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
BR112012008907A2 (pt) 2009-10-15 2020-11-24 Genentech, Inc fatores de crescimento de fibroblastos quiméricos com especificidade receptora alterada
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
JP2013510871A (ja) 2009-11-12 2013-03-28 ジェネンテック， インコーポレイテッド 樹状突起棘の密度を促す方法
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2509626B1 (de) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
SG183335A1 (en) 2010-02-23 2012-09-27 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
RU2015102845A (ru) 2010-02-23 2015-06-10 Санофи АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
AR081750A1 (es) 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
PE20130460A1 (es) 2010-05-03 2013-04-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
BR112012029904A2 (pt) 2010-05-25 2017-08-08 Genentech Inc métodos de purificação de polipeptídeos
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
ES2690760T3 (es) 2010-06-25 2018-11-22 Inserm - Institut National De La Santé Et De La Recherche Médicale Polipéptido de flagelina como agonista de TLR5 para su uso en el tratamiento de infecciones de las vías respiratorias
US8900590B2 (en) 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CA3201524A1 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
AU2011302522A1 (en) 2010-09-15 2013-05-02 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
JP5913326B2 (ja) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド モエシン断片の診断的および治療的使用
WO2012045279A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
US9632098B2 (en) 2010-10-08 2017-04-25 Shanghai Kexin Biotech Co., Ltd. Moesin fragments and uses thereof
EP2624854B1 (de) 2010-10-08 2016-08-03 Shanghai Kexin Biotech Co., Ltd Moesininhibitoren und ihre verwendungen
KR101708533B1 (ko) 2010-10-08 2017-02-20 상하이 켁신 바이오테크 씨오., 엘티디. 재생불량 빈혈과 관련된 모에신 단편
JP2013544084A (ja) 2010-10-29 2013-12-12 アリリクス・インコーポレイテッド 改変されたバレンセンシンターゼポリペプチド、コーディング核酸分子およびその使用
AP3953A (en) 2010-11-04 2016-12-22 Boehringer Ingelheim Int Anti-IL-23 antibodies
KR101941514B1 (ko) 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 개선된 반감기를 가지는 변형된 항체
CN103687619A (zh) 2011-02-14 2014-03-26 特罗科隆科学有限公司 用于对流行性感冒进行治疗以及诊断的组合物以及方法
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CA2828347A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
CA2829968A1 (en) 2011-03-15 2012-09-20 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2714735B1 (de) 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
EP2785744B1 (de) 2011-12-01 2017-10-04 AP Biosciences, Inc. Proteininhibitoren des komplementsystems und der vegf-signalwege sowie verfahren zu ihrer verwendung
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
CA2870769C (en) 2012-04-27 2021-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vascular endothelial growth factor antagonists and methods for their use
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
US9353385B2 (en) 2012-07-30 2016-05-31 Evolva, Inc. Sclareol and labdenediol diphosphate synthase polypeptides, encoding nucleic acid molecules and uses thereof
WO2014037376A1 (en) 2012-09-04 2014-03-13 C5 Ligno Technologies In Lund Ab Stereoselective biosynthesis in microbial host cells
AU2013348029A1 (en) 2012-11-20 2015-07-02 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX proteins
CN104870637A (zh) 2012-12-07 2015-08-26 丹尼斯科美国公司 组合物及使用方法
DK2929022T3 (en) 2012-12-07 2017-02-13 Danisco Us Inc COMPOSITIONS AND METHODS OF USE
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
DK2968466T3 (en) 2013-03-13 2018-10-22 Hoffmann La Roche Reduced oxidation formulations
MY185551A (en) 2013-03-13 2021-05-19 Genentech Inc Antibody formulations
WO2014160497A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Formulations with reduced oxidation
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
EP3085778B1 (de) 2013-03-14 2021-07-07 Evolva, Inc. Valencensynthasepolypeptide, nukleinsäuremoleküle zur codierung davon und verwendungen davon
EP2970875B1 (de) 2013-03-15 2020-04-15 F.Hoffmann-La Roche Ag Zellkulturzusammensetzungen mit antioxidanzien und verfahren zur herstellung von polypeptiden
EP3611180B1 (de) 2013-03-15 2021-12-22 Biomolecular Holdings LLC Hybrides immunglobulin mit nichtpeptidylverbindung
US9441035B2 (en) 2013-03-15 2016-09-13 Genentech, Inc. Cell culture media and methods of antibody production
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AU2014324703C1 (en) 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20240017102A (ko) 2013-12-17 2024-02-06 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
ES2788973T3 (es) 2014-03-14 2020-10-23 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene una unión distinta de peptidilo
KR102494646B1 (ko) 2014-03-20 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 안정화된 피브로넥틴 기반 스캐폴드 분자
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
EP3172339A1 (de) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarker zur verwendung bei der behandlung von erkrankungen im zusammenhang mit il-23a
EP3191526B1 (de) 2014-09-12 2023-02-22 The Board of Trustees of the Leland Stanford Junior University Agonistenmoleküle des wnt-signalwegs
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
US20170211054A1 (en) 2014-09-30 2017-07-27 Dansico Us Inc. Compositions comprising beta mannanase and methods of use
US20170211053A1 (en) 2014-09-30 2017-07-27 Danisco Us Inc. Compositions comprising beta mannanase and methods of use
WO2016054194A1 (en) 2014-09-30 2016-04-07 1/1Danisco Us Inc Compositions comprising beta-mannanase and methods of use
US20170218351A1 (en) 2014-09-30 2017-08-03 Danisco Us Inc. Compositions comprising beta-mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
WO2016081384A1 (en) 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3233107B1 (de) 2014-12-09 2021-01-27 Wentao Zhang Nbp158 und verwendungen davon
WO2016100837A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
EP3234118A1 (de) 2014-12-18 2017-10-25 Danisco US Inc. Manipulierte multifunktionale enzyme und verfahren zur verwendung
JP6758304B2 (ja) 2015-02-04 2020-09-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
AU2016215124B2 (en) 2015-02-06 2020-08-06 The University Of North Carolina At Chapel Hill Optimized human clotting Factor VIII gene expression cassettes and their use
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
CA2984638A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3733698A1 (de) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3-bindende fibronektin-basierte gerüstmoleküle
WO2017117304A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
BR112018010945A2 (pt) 2015-12-30 2018-12-04 Genentech Inc formulações com degradação de polissorbato reduzida
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
CN109071625A (zh) 2016-02-04 2018-12-21 柯瑞斯公司 平滑化突变体和其使用方法
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
CA3018794A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Use of il-23 antibodies for treating generalized pustular psoriasis
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US20180105588A1 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
CN110114465A (zh) 2016-12-20 2019-08-09 诺维信公司 用于戊糖发酵的重组酵母菌株
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
TW201842929A (zh) 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
RS63812B1 (sr) 2018-01-26 2023-01-31 Hoffmann La Roche Il-22 fc kompozicije i postupci primene
SG11202007694UA (en) 2018-02-21 2020-09-29 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
US20210171610A1 (en) 2018-05-02 2021-06-10 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
WO2020033485A1 (en) 2018-08-08 2020-02-13 Genentech, Inc. Use of tryptophan derivatives and l-methionine for protein formulation
ES2955032T3 (es) 2018-09-21 2023-11-28 Hoffmann La Roche Métodos de diagnóstico para el cáncer de mama triple negativo
CA3115887A1 (en) 2018-10-23 2020-04-30 Glycardial Diagnostics, S.L. Antibodies specific for glycosylated apoj and uses thereof
KR20210137520A (ko) 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
CN113795509A (zh) 2019-05-09 2021-12-14 勃林格殷格翰国际有限公司 抗-sema3a抗体及其用于治疗眼或眼部疾病的用途
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2022064494A2 (en) 2020-09-23 2022-03-31 Yeda Research And Development Co. Ltd. Methods and compositions for treating coronaviral infections
KR102546738B1 (ko) 2021-01-04 2023-06-22 씨제이제일제당 주식회사 글루타메이트-시스테인 리가아제 변이체 및 이를 이용한 글루타치온 생산방법
KR102593542B1 (ko) 2021-06-10 2023-10-26 씨제이제일제당 주식회사 슈퍼옥사이드 디스뮤테이즈 1 변이체 및 이를 이용한 글루타치온 또는 그 유도체의 생산방법
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4238988A1 (de) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antikörper gegen sars-cov-2 und verwendungen davon
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
GR76274B (de) * 1981-08-04 1984-08-04 Univ California

Also Published As

Publication number Publication date
DE3280284D1 (de) 1991-02-07
AU560122B2 (en) 1987-04-02
JPS58109427A (ja) 1983-06-29
HK37494A (en) 1994-04-29
AU8779782A (en) 1983-03-10
GB2104902B (en) 1985-04-24
NZ201705A (en) 1986-03-14
EP0073657B1 (de) 1990-12-27
ZA826251B (en) 1983-09-28
IE56711B1 (en) 1991-11-06
JP2511394B2 (ja) 1996-06-26
GB2104902A (en) 1983-03-16
EP0073657A1 (de) 1983-03-09
IE822086L (en) 1983-02-28

Similar Documents

Publication Publication Date Title
ATE59409T1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
AU7752894A (en) Novel antigens and methods thereof
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
EP0992580A3 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
EP0171908A3 (de) Hepatitis-B-Virus-Oberflächenantigen und dessen Herstellung
CA2102918A1 (en) Genetic vaccine for immunodeficiency viruses
EP0291586A3 (de) Rekombinantes Hepatitis-B-Oberflächenantigen und dieses enthaltender Impfstoff
IL90035A0 (en) Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
ES8802162A1 (es) Un procedimiento para la preparacion de una levadura trans- formada con un plasmido recombinante insertado con el gen del virus de la hepatitis b.
EP0342860A3 (de) Neues Protein, Sequenze mit enthaltendem Gene, Vektoren, Verfahren zur Herstellung und Verwendung
FI19992546A (fi) Hepatiitti B:n S- ja PreS2-proteiinien ilmentäminen metylotrofisissa hiivoissa
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
FI833205A0 (fi) Foerfarande foer framstaellning av ett hepatitis b-virusvaccin
EP0068719A3 (de) Desoxyribonukleine Säuren, deren Herstellung und Verwendung
HK140095A (en) Hepatitis surface antigen particle vaccine
EP0062574A3 (de) Synthese von Virusproteinen
AU530195B2 (en) Vaccine for active immunization containing hepatitis b surface and/or e -antigens
ES8602935A1 (es) Un vector reversible
PT69953A (en) Process for preparing a composition comprising a lyophilized herpes virus
MY106731A (en) Novel antigens and methods therefor
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith
ATE52798T1 (de) Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time
RZN Patent revoked